Answers are grounded in this paper and cite their sources.
Recent disappointing results of clinical trials seeking type 1 diabetes (T1D) reversal suggest the need for a reevaluation of our translational efforts. This Commentary explores the need for standards in evaluating therapeutic efficacy in preclinical models of T1D.
No takes yet. Share an insight, caveat, or question.
Mark A. Atkinson (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: